9α,11β-Prostaglandin F₂, a Novel Metabolite of Prostaglandin D₂
Is a Potent Contractile Agonist of Human and Guinea Pig Airways

*Medicine 1 and ‡Clinical Pharmacology, Centre Block, Southampton General Hospital, Southampton, SO9 4XY United Kingdom

Abstract

Prostaglandin (PG) D₂, the predominant prostanoid released from activated mast cells in humans is initially metabolized by reduction of the C-11 keto function to yield 9α,11β-PGF₂. In this study the airway effects of 9α,11β-PGF₂ were compared with those of its epimer 9α,11α-PGF₂ (PGF₂α) and PGD₂. 9α,11β-PGF₂ was a potent contractile agonist of isolated guinea pig trachea and 4-mm human airways in vitro; the potencies of the PGs relative to PGD₂ (1.00) being 0.65 (NS) and 4.08 (P < 0.001) for 9α,11β-PGF₂, and 0.52 (P < 0.01) and 2.40 (P < 0.001) for PGF₂α, respectively. When inhaled as asthmatic subjects, 9α,11β-PGF₂ was a potent bronchoconstrictor agent, being approximately equipotent with PGD₂ and 28–32 times more potent than histamine (P < 0.01). These studies suggest that 9α,11β-PGF₂ is at least equipotent with PGD₂ as a bronchoconstrictor agonist, and in being a major metabolite of PGD₂, could contribute to the bronchoconstrictor effect of this mast cell-derived mediator in asthma.

Introduction

There is considerable interest in the role of prostaglandin D₂ (PGD₂) in the pathogenesis of asthma. Not only is PGD₂ the most potent bronchoconstrictor prostaglandin studied so far in humans, being 3.5 times more potent than prostaglandin F₁α (PGF₁α) (1), but it is also the predominant cyclooxygenase product generated during immunologic activation of human pulmonary mast cells in vitro (2). In addition to its bronchospastic effect, PGD₂ may contribute actively to airway inflammation by stimulating neutrophil chemokinesis (3), causing vasodilation, and increasing postcapillary venule permeability (4). PGD₂ has been shown to synergize with leukotriene B₄ in promoting neutrophil infiltration in human skin (4), to potentiate histamine-induced vascular permeability in rat skin (5), and reduce the threshold at which airways respond to inhaled histamine in asthmatic subjects (6).

It has been suggested that PGD₂ is initially metabolized by reduction of the 3-hydroxycyclopentanone ring to yield cyclopentane-1,3-diol ring of F-series prostaglandins (PGs), with subsequent metabolism by PG 15-15-hydroxydehydrogenase and Δ¹₃-reductase (7, 8). We have recently shown that inhalation of PGF₂α, by either normal or asthmatic subjects resulted in a twofold increase in plasma concentrations of the 13,14-dihydro-15-keto metabolite of PGF₂α. However, when the same concentration of PGD₂ was inhaled, the plasma levels of this metabolite remained unchanged (9). This suggests that degradation of PGD₂ to PGF₂α, with subsequent C-15 oxidation and Δ¹₃-reduction is unlikely to represent a major metabolic pathway for PGD₂ immunologically released from mast cells of human airways.

Recent investigations into the fate of PGD₂ in humans have shown that the predominant route of metabolism is via initial formation of the 11β-hydroxyl epimer of PGF₂α, 9α,11β-PGF₂ (10–12). On examining the metabolic transformation of PGD₂ by human liver in vitro, Roberts and co-workers have provided convincing evidence that PGD₂ is converted exclusively to 9α,11β-PGF₂ (10). They have also shown that after infusion of radiolabeled PGD₂ in a normal volunteer, at least 13 of the PGF ring compounds isolated in the urine had 9α,11β geometry (11). Furthermore, in a patient with systemic mastocytosis with an established overproduction of PGD₂, plasma levels of 9α,11β-PGF₂ correlate closely with the clinical exacerbations of the disease. A concentration of 490 ng/ml has been reported during a severe exacerbation of the disease, a level that is > 80,000 times greater than that present in plasma from a normal subject (10).

In vitro, 9α,11β-PGF₂ is a contractile agonist of human coronary artery strips and is a weak inhibitor of ADP-induced platelet aggregation (13). When injected intravenously into rats it causes hypertension (10). Thus, in view of the biological activities of 9α,11β-PGF₂ and its potential for being generated in large amounts from PGD₂ derived from mast cells of human airways, we have investigated its ability to cause bronchoconstriction in asthmatic and normal subjects. In further experiments we have compared its effects with those of PGD₂ and PGF₂α on isolated guinea pig and human airways.

Methods

In vitro studies

Segments of trachea from male Dunkin-Hartley strain guinea pigs (500–750 g) and 4-mm diameter bronchi from human lung tissue obtained from patients undergoing resection for bronchial carcinoma, were used for these experiments. The tissues were cut spirally, divided into sections 1–2 cm long, and suspended in an organ bath containing Krebs' solution, (composition, in millimoles, KCl, 4.69; KH₂PO₄, 1.18; MgSO₄, 1.03; NaCl, 118.1; NaHCO₃, 25.0; glucose, 11.1; and CaCl₂, 2.5), maintained at 37°C and aerated with 95% O₂ and 5% CO₂. Tension developed by the tissues was measured isometrically, using a Lektromed isometric (force) transducer (type 4155) and an Ormed Multitrace six-channel re-

---

1. Abbreviations used in this paper: 9α,11β-PGF₂, 9α,11β-prostaglandin F₂; EC₅₀, response level corresponding to 50% of prostaglandin D₂ maximum; FEV₁, forced expiratory volume in 1 s; PC, provocation concentration; PGs, prostaglandins; PGD₂, prostaglandin D₂; PGF₂α, prostaglandin F₂α; sGaw, specific airways conductance; TLC, total lung capacity; Vmax, maximum airflow rate at a lung volume of 30% of initial vital capacity.

J. Clin. Invest. © The American Society for Clinical Investigation, Inc. 0021-9738/87/03/0978/06 $1.00
Volume 79, March 1987, 978–983

---
corder. Tissues were suspended with initial tension of 5 g and allowed to equilibrate for 1 h. All of the guinea pig tracheal spirals and 70% of the human bronchial spiral preparations gave consistent contractile responses to the initial supramaximal (1 × 10^{-4} M) concentration of methacholine, and these were therefore considered suitable for analysis of PG effects. Cumulative dose–response curves were constructed for PGD_2, 9α,11β-PGF_2, and PGF_2α (0.1–32.0 × 10^{-4} M). Preliminary experiments had demonstrated that the human bronchial spiral was resistant to desensitization by all three PGs used, and that the guinea pig trachea exhibited desensitization only when exposed to higher doses of PGs (> 32 × 10^{-4} M) for longer periods (45 min) than those used in these experiments. PGs were made up freshly for each study in Krebs' solution and tested in a random order.

In vivo studies

Subjects. Eight men with mild allergic asthma participated in this study. All gave histories of episodic dyspnea with wheezing and had at least a 15% improvement in forced expiratory volume in 1 s (FEV_1) in response to albuterol. Their mean age (±SEM) was 29±2 y, and all were nonsmokers. The mean baseline FEV_1 (±SEM) was 70.7±5.9% of the predicted normal values. All eight subjects were being treated with inhaled albuterol, and in addition, two were receiving inhaled beclomethasone dipropionate. No other medications were taken by any of the subjects during the study. Inhaled treatment was withheld for at least 8 h before the inhalation tests.

Five normal nonallergic men participated as matched control subjects. Their mean age (±SEM) was 25±2 y, and all were nonsmokers on no medication. Their mean baseline FEV_1 (±SEM) was 91.8±1.6% of the predicted normal values. The study was approved by the Southampton University Hospitals Ethical Committee and subjects gave their informed consent.

Airway measurements. Airway resistance and thoracic gas volume were measured in a pressure-compensated, volume displacement whole body plethysmograph (Fenyes & Gut, Basle, Switzerland), with subjects panting at 2 Hz over 12 s. The signal was automatically computed to mean values for specific airways conductance (sGaw) by an on-line microprocessor, to take account of variations in lung volume at which measurements of airway resistance were made (14). FEV_1 and the maximum expiratory flow rate at a lung volume of 30% of the initial vital capacity (Vmax_{65}) were measured by a rolling seal spirometer (Morgan Spirflow 12L, P. K. Morgan Ltd., Gillingham, Kent, UK) linked to a Hewlett-Packard 85B microcomputer. Subjects were instructed to perform a partial expiratory maneuver beginning at 50% total lung capacity (TLC), which was followed by a maximum forced expiration from TLC. Vmax_{65} was measured during the initial partial expiration to avoid changes in airway caliber that may occur immediately following both a forced expiration and inspiration to TLC. For this reason also, the forced maneuvers were performed after measurement of sGaw and the second test repeated 1 min after the first.

Drug administration. Histamine acid monophosphate (BDH Chemicals Ltd., Poole, Dorset, UK) was made up freshly each day in 0.9% saline to produce a range of concentrations from 0.10–13.0 × 10^{-3} M. PGD_2 and 9α,11β-PGF_2 (Salford Ultradeine Chemicals and Research Ltd., Salford, UK) were dissolved as stock solutions in methanol at a concentration of 113.0 × 10^{-3} M, respectively, and stored at −20°C under nitrogen. The 9α,11β-PGF_2 was prepared from the Corey lactone using methods previously described (15). The identity and purity was verified by 360-MHz proton magnetic resonance spectroscopy and capillary column gas chromatography/mass spectrometry in the electron impact mode using the methyl ester, methoxime, trimethylsilyl ether derivatives. The mass spectrum contained fragments identical to those reported by Liston and Roberts (10) and was chromatographically distinct from PGF_2α using a 10-meter DB-5 column (i.d. 0.32 mm, helium flow 1 ml/min). Further confirmation was obtained by high performance liquid chromatography on two separate reversed phase systems and inclusion complexing on cycloexdrin in beta, in which the purity was measured as 95%. PGF_2α (The Upjohn Co., Crawley, Sussex, UK) was obtained as a sterile aqueous solution of 14.1 × 10^{-3} M of the tromethamine salt in 0.9% benzyl alcohol. Immediately before use, aliquots of the PGs were diluted with 0.15 M sodium phosphate vehicle (pH 7.4) to achieve a range of concentrations from 0.0028 to 11.3 × 10^{-3} M. Placebo consisted of 0.9% saline before the inhalation of histamine, and phosphate buffer containing 0.01% of methanol before the PG inhalation. The drugs were nebulized from a starting volume of 1.0 ml using an Inspiron nebuliser (CR Bard International Ltd., Sunderland, UK) driven by compressed air and triggered by a Rosenthal-French dosimeter with a delivery time of 0.74 s. Aerosols with a mass median particle diameter of 4.7 μm were inhaled using a method modified from that of Chai et al. (16). The subjects took five breaths from functional residual capacity to TLC through a mouthpiece while wearing a noseclip. Under these conditions 34 μl of solution leaves the nebulizer with a coefficient of variation of 11%.

Protocol. In the dose–response studies, the asthmatic subjects attended the laboratory on four occasions, separated by at least 4 d, to inhale placebo followed by increasing concentrations of either histamine, PGD_2, 9α,11β-PGF_2, or PGF_2α. The control subjects attended the laboratory once to inhale placebo followed by increasing concentrations of 9α,11β-PGF_2. Six measurements of sGaw and three measurements of FEV_1, and Vmax_{65} were made at 1-min intervals to obtain mean baseline values. The appropriate vehicle placebo was then administered and followed by two measurements of sGaw, FEV_1, and Vmax_{65}. The agonists were then administered in a series of doubling concentrations at 6-min intervals. After each dose, sGaw was measured at 1 and 2.5 min, and then FEV_1, and Vmax_{65} at 3 and 4 min. The inhalations and measurements were continued until FEV_1 had fallen by >20% of the post-placebo value or until the maximum concentration of agonist had been administered. The PGs were administered double-blind and in random order.

For the time course study, a single concentration (0.71 × 10^{-3} M) of PGD_2, 9α,11β-PGF_2, and PGF_2α was administered to six subjects on three separate occasions at least 4 d apart. Two patients (Nos. 2 and 4) demonstrated to have highly reactive airways in the dose–response studies, were not studied in the time course study for ethical reasons, because the concentration of PG inhaled was likely to cause severe bronchospasm. Six measurements of sGaw were made at 1-min intervals to obtain a mean baseline value. Placebo was then inhaled and sGaw measured at 3-min intervals for 15 min. The PG solution was then administered and single measurements of sGaw were made at regular intervals up to 45 min post-challenge.

For the isolated airway preparations, contractile responses for each PG were expressed as a percentage of the maximum achieved with methacholine. Dose–response curves were constructed by plotting the contractile response against the agonist concentration on a logarithmic scale. To compare the relative potencies of the PGs, the concentrations required to produce a response 50% of the maximum for PGD_2 (EC_{50}) and associated 95% confidence limits were determined by linear regression analysis. The significance of differences in the relative potencies were determined by analysis of variance, and probability values of 0.05 or less were considered to represent statistically significant differences.

For the in vivo dose–response studies, the airway response to provocation with a test substance was expressed as percentage change from the post-placebo baseline value for each of the three indices of airway caliber. For FEV_1, the lower of the two values recorded at each concentration was expressed as a percentage of the lower of the post-placebo baseline measurements. To accommodate for the greater intra-subject variation for the measurement of sGaw and Vmax_{65}, the mean of two values recorded at each concentration was expressed as a percentage of the mean of the two post-placebo baseline measurements. Dose–response curves were constructed by plotting the percentage fall against the logarithm of the agonist concentration. Provocation concentration (PC) values were obtained from each dose–response curve by linear interpolation from the last two points, and geometric mean values calculated for the group. The PC_{50} FEV_1 was the concentration of drug producing a 20% fall in FEV_1; the PC_{50} sGaw, a 35% fall in sGaw; and the PC_{50} Vmax_{65}, a 50% fall in Vmax_{65}. Covariant analysis was used to assess whether the concentration effect curves differed significantly from parallel.

Airway Effects of 9α,11β-Prostaglandin F_2α
and the significance of differences in PC values evaluated by Wilcoxon signed rank test. Correlations between the PC values for the different agonists were established using linear regression.

For the time course study, the percentage fall in sGaw from the mean baseline value measured 15 min after administration of placebo was calculated at each time point. The resultant maximum percentage fall in sGaw, the area under the time–response curve (calculated by trapezoidal integration), and the rate of recovery from maximum fall to 50% of maximum were compared between agonists by the Wilcoxon signed rank test.

Results

PGD$_2$, 9α,11β-PGF$_2$, and PGF$_{2\alpha}$ all caused concentration-related contractions of both isolated guinea pig trachea and human bronchus (Fig. 1). There was considerable variability in the responsiveness of both guinea pig and human airway preparations to the PGs (Table I).

In the guinea pig trachea, the maximal responses of the PGs did not differ significantly from each other, and were small when compared with that of methacholine. The relative potencies of the PGs were compared at a response level corresponding to 10% of the methacholine maximum, which corresponds to the EC$_{50}$ for PGD$_2$. The potencies of the PGs relative to PGD$_2$ (EC$_{50}$ = 1.00) were 9α,11β-PGF$_2$ 0.65 (NS) and PGF$_{2\alpha}$ 0.52 (P < 0.01) (Table I).

In human bronchus, the maximum responses for the PGs relative to that of MCh were similar being 92.2±1.7% at 32 μM PGD$_2$, 95.1±2.0% at 10 μM 9α,11β-PGF$_2$, and 93.1±1.0% at 10 μM PGF$_{2\alpha}$ (n = 3). Because these values were not significantly different, subsequent PG concentration–response studies were performed to obtain responses up to 75% of the MCh maximum in the same tissue. The relative potencies of PGs compared at 50% of the maximum response to MCh (which corresponds to the EC$_{54}$ for PGD$_2$) were 1.00 for PGD$_2$, 4.08 for 9α,11β-PGF$_2$ (P < 0.001), and 2.40 for PGF$_{2\alpha}$ (P < 0.001) (Table I).

In vivo

Asthmatic subjects. There was no significant difference between the mean baseline measurements of FEV$_1$, sGaw, and Vmax$_{30}$ on the different treatment days during either the dose–response or time course studies, either before or after administration of placebo.

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Guinea pig trachea</th>
<th>Human bronchial spiral</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>PGD$_2$</td>
<td>0.25 (0.11, 0.55)*</td>
<td>17</td>
</tr>
<tr>
<td>9α,11β-PGF$_2$</td>
<td>0.38 (0.18, 0.78)</td>
<td>19</td>
</tr>
<tr>
<td>PGF$_{2\alpha}$</td>
<td>0.47 (0.28, 0.78)</td>
<td>18</td>
</tr>
</tbody>
</table>

*n, No. of preparations tested.
* Geometric mean (95% confidence limits).

Histamine, PGD$_2$, and 9α,11β-PGF$_2$ all caused concentration-related falls in FEV$_1$, sGaw, and Vmax$_{30}$. PGF$_{2\alpha}$ caused a concentration-related fall in measurements of airway caliber in four asthmatic subjects (Nos. 2, 4, 5, and 8) three of whom had the lowest PC$_{20}$ FEV$_1$ values for histamine. The remaining four subjects responded to PGF$_{2\alpha}$ with a bi- or triphasic response (Nos. 1, 3, 6, and 7). These reactions were characterized by initial bronchoconstriction at concentrations up to 1.0 X 10$^{-4}$ M, followed by reversal at intermediate concentrations, and in subjects 1 and 6 further bronchoconstriction at concentrations > 1.0 X 10$^{-3}$ M. When this type of response occurred with PGF$_{2\alpha}$, it was observed with all three indices of airway caliber. Fig. 2 shows the different patterns of airway response to inhaled PGF$_{2\alpha}$ for patients 3, 4, and 6, and Fig. 3 shows the corresponding dose–response curves to histamine, PGD$_2$, and 9α,11β-PGF$_2$ for these same patients.

Table II depicts geometric mean provocation concentrations and relative potency ratios (histamine = 1.0) for the three different methods of measuring airway caliber. PGD$_2$ and 9α,11β-PGF$_2$ were 26–54 and 28–32 times more potent than histamine as bronchoconstrictor agents. Due to the complex nature of the concentration–response curves to PGF$_{2\alpha}$ in four of the eight subjects, no direct comparisons were possible between PGF$_{2\alpha}$ and the other constrictor agonists. There was a close correlation

![Figure 1](image1.png)

**Figure 1.** (a) Guinea-pig trachea. Contractile response observed with increasing concentrations of PGD$_2$ (open triangles), 9α,11β-PGF$_2$ (open circles), and PGF$_{2\alpha}$ (filled circles) for guinea-pig trachea spirals. Each point represents the mean (±SEM) contractile response as percent of methacholine maximum, 17–19 preparations. (b) Human bronchus. Contractile response observed with increasing concentrations of PGD$_2$ (open triangles), 9α,11β-PGF$_2$ (open circles), and PGF$_{2\alpha}$ (filled circles) for human bronchial segments. Each point represents the mean (±SEM) contractile response as percent of methacholine maximum, 8–10 preparations.

![Figure 2](image2.png)

**Figure 2.** The changes in airway caliber after the inhalation of increasing concentrations of PGF$_{2\alpha}$ in three asthmatic subjects (Nos. 3, 4, and 6; A, B, and C, respectively). Each point represents the percent of baseline for FEV$_1$ (open triangles), sGaw (open circles), and Vmax$_{30}$ (filled circles).
between the airway responsiveness to histamine, PGD₂, and 9α,11β-PGF₂ (Table III).

In the time course study, all three PGs caused a fall in sGaw with the maximum airway response occurring between 3 and 7 min after aerosol inhalation (Fig. 4). The mean (±SEM) maximum fall for 9α,11β-PGF₂ was 48±14% and this was significantly greater than the fall caused by PGD₂ (39±12%, P < 0.01) and that after PGF₂α. The areas under the time course sGaw response curves for 9α,11β-PGF₂ were significantly greater than that of PGF₂α (P < 0.01), but were not significantly different from those of PGD₂. Bronchoconstriction with 9α,11β-PGF₂ persisted for longer than the 45 min of the study period, whereas return to baseline sGaw for PGD₂ and PGF₂α had occurred by 45 and 25 min, respectively. Despite the greater duration and magnitude of bronchoconstriction observed with 9α,11β-PGF₂, the rates of recovery of airway caliber were not significantly different between the PGs.

Nonasthmatic subjects. Inhalation of 9α,11β-PGF₂ caused concentration-related falls in all three indices of airway caliber. After inhalation of the maximum concentration of 9α,11β-PGF₂ (11.3 × 10⁻³ M), the FEV₁ did not fall by > 20% of the post-placebo value in any of the five control subjects (range, +3 to −19%). The mean maximum fall (±SEM) at this maximum concentration was 23.0±8.2, 6.6±8.1, and 39.2±17.3% for sGaw, FEV₁, and Vmax₉₀, respectively. This contrasts with the response observed with all the asthmatic subjects in which a fall in FEV₁ of at least 20% was achieved before reaching this maximum concentration of 9α,11β-PGF₂.

Discussion

This study demonstrates for the first time that a product of the principal pathway of PGD₂ metabolism in humans, 9α,11β-PGF₂ (10–12), is a contractile agonist of isolated guinea pig and human airways. In vitro it was more potent than PGD₂ on human airways, and more potent than its 11α-epimer PGF₂α on both guinea pig and human airways. In accordance with the in vitro studies, 9α,11β-PGF₂ constricted the airways of normal and asthmatic subjects in vivo. In the asthma group it was approximately equipotent with PGD₂, and 28–32 times more potent than histamine as a bronchoconstrictor agent.

It has been suggested that the measurements Vmax₉₀ and sGaw reflect dimensions of the airways at different levels in the bronchial tree, Vmax₉₀ comprising a major small airway component (17) and sGaw a large component being derived from the more proximal airways (18). The greater potency of inhaled 9α,11β-PGF₂ and PGD₂, when compared with histamine was of similar magnitude irrespective of whether sGaw, FEV₁, or Vmax₉₀ were used to measure airway caliber. This may indicate that both prostanoids have similar contractile activities on central and peripheral airways, or that the physiological measurements are insensitive in detecting small regional differences in airway dimensions (19). The high degree of correlation observed between the PC values of 9α,11β-PGF₂ with those of both histamine and PGD₂, and the less marked effect in provoking bronchoconstriction in normal subjects, indicates that the airway responsiveness to 9α,11β-PGF₂ is related to the degree of nonspecific bronchial reactivity.

Narumiya and Toda (20) have recently described three operationally distinct receptor mechanisms for the pharmacologic effects of PGD₂, with the contractile activity on airway and cerebral artery smooth muscle being distinct from that linked to adenylyl cyclase mediating the platelet and mast cell effects and also different from that inhibiting tumor cell growth.

Table II. Geometric Mean PCs and Relative Potency Ratios of Inhaled Histamine, PGD₂, and 9α,11β-PGF₂ for Different Measurements of Airway Caliber in Asthmatic Subjects

<table>
<thead>
<tr>
<th>Agonist</th>
<th>PC₂₀ FEV₁</th>
<th>PC₂₀ sGaw</th>
<th>PC₉₀ Vmax₉₀</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Geometric mean (×10⁻³ M)</td>
<td>Geometric mean (×10⁻³ M)</td>
<td>Geometric mean (×10⁻³ M)</td>
</tr>
<tr>
<td>Histamine</td>
<td>2.36</td>
<td>2.27</td>
<td>2.02</td>
</tr>
<tr>
<td>PGD₂</td>
<td>0.15⁴</td>
<td>0.11³</td>
<td>0.10*</td>
</tr>
<tr>
<td>9α,11β-PGF₂</td>
<td>0.17⁴</td>
<td>0.14³</td>
<td>0.10³</td>
</tr>
</tbody>
</table>

Significance of differences from histamine (rank Wilcoxon test). * P < 0.05. † P < 0.01.
Table III. Correlation between PCs of 9α,11β-PGF₂ and Those of Histamine and PGD₂, for the Three Different Measurements of Airway Caliber in Asthmatic Subjects

<table>
<thead>
<tr>
<th>Agonist</th>
<th>PC₉₀ FEV₁ (×10⁻³ M)</th>
<th>PC₉₀ tGaw (×10⁻³ M)</th>
<th>PC₉₀ Vmax₉₀ (×10⁻³ M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histamine</td>
<td>0.78*</td>
<td>0.61†</td>
<td>0.77*</td>
</tr>
<tr>
<td>PGD₂</td>
<td>0.91†</td>
<td>0.72‡</td>
<td>0.95‡</td>
</tr>
</tbody>
</table>

Mean least-square linear regression.
* P < 0.02.
† NS.
‡ P < 0.05.
§ P < 0.001.

Whereas in the present study a potency difference was observed between 9α,11β-PGF₂ and PGD₂ on human airway in vitro, no such difference was observed in vivo or in guinea pig trachea in vitro. We are therefore unable to comment on whether the bronchoconstrictor effects of the two prostanoids are mediated through the same receptor as might be suggested from their similar activities on human coronary artery strips and platelet aggregation (21).

We have recently demonstrated that histamine may contribute up to 50% of the immediate allergen-induced asthmatic response in vivo (22). After immunologic activation, the human pulmonary mast cell releases between 40 and 50 times more histamine than PGD₂ (23). Our observation that PGD₂ and 9α,11β-PGF₂ are between 26 and 54 times more potent than histamine as bronchoconstrictor agonists when inhaled in vivo, suggests that both these PGs have a physiologic effect comparable to that of histamine in producing bronchoconstriction after allergen challenge. This would indicate that PGD₂ and its initial metabolite 9α,11β-PGF₂ may contribute significantly to the immediate allergen-induced asthmatic response.

In contrast to PGD₂ and 9α,11β-PGF₂, the concentration response relationship with PGF₂α was complex. Four of the eight asthmatic subjects tested had a single concentration response curve, while the remaining subjects demonstrated a bi- or triphasic response to increasing concentrations of inhaled PGF₂α. Although this precluded direct measurement of its bronchoconstrictor potency in vivo, we were able to obtain a rank assessment of activity of PGF₂α relative to 9α,11β-PGF₂ from the time course and in vitro studies, both of which suggested that 9α,11β-PGF₂ was more potent than PGF₂α. The mechanisms causing the multiphasic responses to PGF₂α may involve a complex interaction between vagal stimulation (24), tachyphylaxis (25), and release of a bronchodilator substance.

We conclude that 9α,11β-PGF₂, a metabolite of PGD₂ found in substantial quantities during mast cell activation in man (10, 12), is also a potent bronchoconstrictor agonist. In view of the recent observations that PGD₂ is preferentially metabolized by human lung to 9α,11β-PGF₂ (26), our studies suggest that at least some of the bronchoconstrictor activity of PGD₂ could be achieved after its local biotransformation to 9α,11β-PGF₂. Thus, 9α,11β-PGF₂ is a novel bronchoconstrictor prostanoid whose activity may contribute to the pathogenesis of airflow obstruction in patients with allergic asthma.

Acknowledgments

We are indebted to Mrs. M. Dowling and Mrs. S. Foulkes for preparation of the manuscript.

We thank the Wellcome Foundation, Medical Research Council of New Zealand, the Asthma Research Council, and the Chest, Heart and Stroke Association of Great Britain for financial support.

References


Figure 4. Time course of bronchoconstriction induced by a single inhalation of PGD₂ (open triangles), 9α,11β-PGF₂ (open circles), of PGF₂α (filled circles) in asthmatic subjects. Each point represents the mean (±SEM) percent of baseline for sGaw in six subjects. The concentration of each prostanoid inhaled was 0.71 × 10⁻³ M.


Airway Effects of 9α,11β-Prostaglandin F2, 983